A Histologic Study of Imatinib Cardiotoxicity in Adult Male Rats
DOI:
https://doi.org/10.3889/oamjms.2023.8826Keywords:
Cardiotoxicity, Oxidative stress, rat, HistopathologyAbstract
BACKGROUND: Cardiotoxicity is an unanticipated adverse effect associated with some chemotherapeutic agents. There are conflicting results about imatinib-induced cardiac toxicity.
AIM: This study aims at investigating the possible cardiotoxic effects of imatinib in rat model through assessing the possible histopathological alterations that might develop.
MATERIALS AND METHODS: This is a case–control and experimental study conducted over a period of 3 months at laboratory of postgraduate studies, Department of Anatomy, College of Medicine, University of Mosul, Mosul, Northern Iraq. Sixteen adult male Albino rats were randomly assigned to either “control group” or “imatinib-treated group.” The control group was gavaged with distilled water daily for 4 weeks while the second group was given oral imatinib (200 mg/kg/day) for the same duration. Animals were sacrificed by euthanization after 24 h of the last dose. Hearts were obtained and cardiac specimens were immersed in paraffin. Sections’ staining by hematoxylin (Harris)-eosin (H&E) and Massons’ Thrichrom.
RESULTS: Rats treated with imatinib showed decreased physical activity and food intake. Regular arrangements of myofilaments were noticed during light microscopic examination of cardiac sections of control rats. However, sections from imatinib group showed several histological alterations (mainly myofibrillar loss in myocardium with vacuolated cytoplasm). Necrosis of cardiac muscle fibers was also noticed in some sections. Appearance of deeply staining cells with pyknotic nucleus, in addition to shrinkage of cardiac muscle fibers, was also noticed in some sections. The mean score of cardiac injury in the treated group was 2.1 (vs. 0.6 in controls). Some sections of treated group showed an increment (mild) in collagen fibers in-between cardiac myocytes.
CONCLUSIONS: The observations concluded that imatinib has targeted action on cardiomyocytes. Oncologists should be cautious regarding imatinib dose and duration besides the close cardiac monitoring throughout and beyond therapy duration.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Howell ST, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7(4):363-9. https://doi.org/10.1093/humupd/7.4.363 PMid:11476348 DOI: https://doi.org/10.1093/humupd/7.4.363
Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol. 2006;58(4):567-73. https://doi.org/10.1211/ jpp.58.4.0017 PMid:16597375 DOI: https://doi.org/10.1211/jpp.58.4.0017
Maharsy W, Aries A, Mansour O, Komati H, Nemer M. Ageing is a risk factor in imatinib mesylate cardiotoxicity. Eur J Heart Fail.
;16(4):367-76. https://doi.org/10.1002/ejhf.58 PMid:24504921 DOI: https://doi.org/10.1002/ejhf.58
Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med.
;349(15):1451-64. https://doi.org/10.1056/NEJMra020777 PMid:14534339 DOI: https://doi.org/10.1056/NEJMra020777
Nadal, E, Olavarria E. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukemia and other malignances. Int J Clin Pract. 2004;58(5):511-6. https://doi.org/10.1111/j.1368-5031.2004.00173.x PMid:15206509 DOI: https://doi.org/10.1111/j.1368-5031.2004.00173.x
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332-44. https://doi.org/10.1038/nrc2106 PMid:17457301 DOI: https://doi.org/10.1038/nrc2106
Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. J Clin Oncol. 2003;21(11):2138-46. https://doi.org/10.1200/JCO.2003.12.154 PMid:12775739 DOI: https://doi.org/10.1200/JCO.2003.12.154
Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrationsinpreclinicalstudies.LeukRes.2010;34(9):1180-8. https://doi.org/10.1016/j.leukres.2010.01.004 PMid:20122731 DOI: https://doi.org/10.1016/j.leukres.2010.01.004
Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A, Somay A. Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: Mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod. 2009;24(7):1717-25. https://doi.org/10.1093/humrep/dep058 PMid:19279034 DOI: https://doi.org/10.1093/humrep/dep058
Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol. 2011;39(7):1091-106. https://doi.org/10.1177/0192623311419524 PMid:21937741 DOI: https://doi.org/10.1177/0192623311419524
Swamy AH, Patel UM, Koti BC, Gadad PC, Patel NL, Thippeswamy AH. Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: A biochemical, electrocardiographic and histopathological study. Indian J Pharmacol. 2013;45(1):44-8. https://doi.org/10.4103/0253-7613.106434 PMid:23543849 DOI: https://doi.org/10.4103/0253-7613.106434
Mohan M, Bhandare S. Protective effect of Solanum torvum against testicular toxicity in male Wistar rats. Int J Pharm Pharm Sci. 2012;4(3):188-92.
Favareto AP, Fernandez CD, da Silva DA, Anselmo-Franci JA, De Grava Kempinas W. Persistent impairment of testicular histology and sperm motility in adult rats treated with Cisplatin at peri-puberty. Basic Clin Pharmacol Toxicol. 2011;109(2):85-96. https://doi.org/10.1111/j.1742-7843.2011.00688.x PMid:21410649 DOI: https://doi.org/10.1111/j.1742-7843.2011.00688.x
Abarikwu SO, Otuechere CA, Ekor M, Monwuba K, Osobu D. Rutin ameliorates cyclophosphamide-induced reproductive toxicity in male rats. Toxicol Int. 2012;19(2):207-14. https://doi. org/10.4103/0971-6580.97224 PMid:22778522 DOI: https://doi.org/10.4103/0971-6580.97224
Al-Allaf LI, Al-Ashoo HA. The effects of imatinib on the testicular histology in male rats administered at peripubertal period. JABHS. 2014;15(1):24-34.
Gado AM, Adam AI, Aldahmash BA. Cardiotoxicity induced by cyclophosphamide in rats: Protective effect of curcumin. J Res Environ Sci Toxicol. 2013;2(4):87-95.
Chintalgattu V, Khakoo AY. Cardiovascular toxicities due to molecularly targeted cancer therapeutics. Clin Adv Hematol Oncol. 2010;8(2):133-5.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172-87. https://doi.org/10.1056/NEJMra044389 PMid:16014887 DOI: https://doi.org/10.1056/NEJMra044389
Cohen MH, Johnson JR, Pazdur R. U.S. Food and drug administration drug approval summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res. 2005;11(1):12-9. PMid:15671523 DOI: https://doi.org/10.1158/1078-0432.12.11.1
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-16. https://doi.org/10.1038/nm1446 PMid:16862153 DOI: https://doi.org/10.1038/nm1446
Schellings MW, Lowenberg B, Pinto YM. Another look at imatinib mesylate. N Engl J Med. 2007;356(11):1183. https://doi.org/10.1056/nejmc063721 PMid:17361003 DOI: https://doi.org/10.1056/NEJMc063721
Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol.
;22(3):409-29. https://doi.org/10.1016/j.beha.2009.06.001 PMid:19959091 DOI: https://doi.org/10.1016/j.beha.2009.06.001
Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36(10):1199-207. https://doi.org/10.1016/j.freeradbiomed.2004.02.074 PMid:15110384 DOI: https://doi.org/10.1016/j.freeradbiomed.2004.02.074
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21-34. https://doi.org/10.1161/CIRCRESAHA.109.206920 PMid:20056943 DOI: https://doi.org/10.1161/CIRCRESAHA.109.206920
Kostin S. Pathways of myocyte death: Implication for development of clinical laboratory biomarkers. Adv Clin Chem. 2005;40:37-98. https://doi.org/10.1016/s0065-2423(05)40002-5 PMid:16355920 DOI: https://doi.org/10.1016/S0065-2423(05)40002-5
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9. https://doi.org/10.1016/S0140-6736(07)61865-0 PMid:18083403 DOI: https://doi.org/10.1016/S0140-6736(07)61865-0
Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as a marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83(6):517-8. https://doi.org/10.1002/ajh.21157 PMid:18306359 DOI: https://doi.org/10.1002/ajh.21157
Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, et al. Distinct roles of c-Ab1 and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 2004;18(5):1824-37. https://doi.org/10.1101/gad.1223504 PMid:15289456 DOI: https://doi.org/10.1101/gad.1223504
Nilsson I, Shibuya NM, Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res. 2004;299(2):476-85. https://doi.org/10.1016/j.yexcr.2004.06.005 PMid:15350545 DOI: https://doi.org/10.1016/j.yexcr.2004.06.005
Hassan NA, Yousef MM. Study of imatinib cardiotoxicity in adult male rabbits. IOSR J Enviro Sci Toxicol Food Technol. 2013;6(5):14-26. DOI: https://doi.org/10.9790/2402-0651426
Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J. 2009;19(1):1-11. https://doi.org/10.1096/fj.04-2370com PMid:15629889 DOI: https://doi.org/10.1096/fj.04-2370com
Rosenbloom J, Castro SV, Jimenez SA. Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152(3):159-66. https://doi.org/10.7326/0003-4819-152-3-201002020-00007 PMid:20124232 DOI: https://doi.org/10.7326/0003-4819-152-3-201002020-00007
Downloads
Published
How to Cite
License
Copyright (c) 2023 Luma Al-Allaf, Wahda Alnuaeimy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
